サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1405775

てんかん治療薬の市場規模、シェア、動向分析レポート：製品別、地域別、セグメント予測、2023年～2030年

Epilepsy Drugs Market Size, Share & Trends Analysis Report By Product (First Generation Anti-epileptics, Second Generation Anti-epileptics, Third Generation Anti-epileptics), By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 91 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
てんかん治療薬の市場規模、シェア、動向分析レポート：製品別、地域別、セグメント予測、2023年～2030年
出版日: 2023年12月04日
発行: Grand View Research
ページ情報: 英文 91 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

てんかん治療薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、てんかん治療薬の世界市場規模は、2023年から2030年にかけて5.1%のCAGRを記録し、2030年には153億5,000万米ドルに達すると予測されています。

てんかん発作の治療に有効な新薬の市場開拓に対する政府資金の増加は、てんかん治療薬市場成長の影響の大きい促進要因です。米国てんかん協会（AES）は、米国神経学会（American Academy of Neurology）、てんかん財団（Epilepsy Foundation）、グラス財団（Grass Foundation）などのその他の組織と連携して、研究開発活動への資金を提供し、さまざまなプログラムを通じて医師に治療ラインの認識トレーニングを提供しています。

さらに、Epilepsy Foundation、American Epilepsy Society、Epilepsy Association of Central Florida、CURE Epilepsy、Anita Kaufmann Foundationなどの団体が実施する様々な啓発プログラムは、診断率と治療率をさらに加速させています。このことは、予測期間中の市場成長を促進すると予想されます。

てんかん治療薬市場レポートハイライト

  • 第二世代の抗てんかん治療薬は、第二の急成長セグメントとなる見込み。このセグメントには、Lamotrigine（Lamictal）、Levetiracetam（Keppra）、Brivaracetam（Briviact）、Perampanel（Fycompa）などが含まれます。
  • 第3世代の抗てんかん治療薬セグメントは、2022年に約39.3%の最大の売上シェアを占めました。同分野の成長の主な要因としては、作用機序が改善され副作用の少ない有効性の高い薬剤の上市や、新たなパイプライン薬剤の上市待ちなどが挙げられます。
  • 2022年の売上高シェアは北米が約45%と最も高く、市場を独占しています。同地域ではてんかんの有病率が高く、罹患者数が多いことが、てんかん治療薬市場の主な牽引要因となっています。
  • アジア太平洋地域は予測期間中、CAGR 6.3%と最も高い伸びを示すと推定されます。てんかんに関するセクター間世界行動計画、てんかんに対する世界キャンペーンなどの政府イニシアティブの存在や、新世代の抗てんかん治療薬の発売が、同地域における同市場の成長を促進する要因として期待されています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 普及と成長の見通しマッピング
  • 世界のてんかん治療薬市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 てんかん治療薬市場：製品の推定・動向分析

  • てんかん治療薬市場：重要なポイント
  • てんかん治療薬市場：製品動向と市場シェア分析、2022年および2030年
  • 第一世代抗てんかん治療薬
  • 第二世代抗てんかん治療薬
  • 第三世代抗てんかん治療薬

第5章 てんかんの薬市場：地域の推定・動向分析、薬剤別

  • 地域別の見通し
  • 地域別のてんかんの薬市場：マーケットプレースにおける重要なポイント
  • 北米
    • 市場推計・予測、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • スウェーデン
    • ノルウェー
    • デンマーク
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • アラブ首長国連邦
    • クウェート

第6章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 市場参入企業の分類
    • UCB SA、ベルギー
    • サノフィ
    • ファイザー株式会社
    • 大塚アメリカ製薬株式会社
    • エーザイ株式会社
    • ノバルティスAG
    • アボット・ラボラトリーズ株式会社
    • サノフィアベンティス SA
    • グラクソ・スミスクラインplc
    • サノビオン・ファーマシューティカルズ株式会社
    • ジャズ・ファーマシューティカルズ・ピーエルシー
    • ニューレリス株式会社
図表

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 3 North America epilepsy drugs market, by country, 2018 - 2030 (USD Million)
  • Table 4 U.S. epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 5 Canada epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 6 Europe epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 7 Europe epilepsy drugs market, by country, 2018 - 2030 (USD Million)
  • Table 8 Germany epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 9 UK epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 10 France epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 11 Italy epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 12 Spain epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 13 Sweden epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 14 Norway epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 15 Denmark epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 16 Asia Pacific epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 17 Asia Pacific epilepsy drugs market, by country, 2018 - 2030 (USD Million)
  • Table 18 China epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 19 Japan epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 20 India epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 21 Thailand epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 22 Australia epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 23 South Korea epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 24 Latin America epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 25 Latin America epilepsy drugs market, by country, 2018 - 2030 (USD Million)
  • Table 26 Brazil epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 27 Mexico epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 28 Argentina epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 29 Middle East and Africa epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 30 Middle East and Africa epilepsy drugs market, by country, 2018 - 2030 (USD Million)
  • Table 31 South Africa epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 32 Saudi Arabia epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 33 UAE epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 34 Kuwait epilepsy drugs market, by product, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Epilepsy drug market: Market outlook
  • Fig. 9 Epilepsy drug market: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Epilepsy drug market driver impact
  • Fig. 15 Epilepsy drug market restraint impact
  • Fig. 16 Epilepsy drug market strategic initiatives analysis
  • Fig. 17 Epilepsy drug market: Product movement analysis
  • Fig. 18 Epilepsy drug market: Product outlook and key takeaways
  • Fig. 19 First generation anti-epileptics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Second generation anti-epileptics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Third generation anti-epileptics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Global epilepsy drug market: Regional movement analysis
  • Fig. 23 Global epilepsy drug market: Regional outlook and key takeaways
  • Fig. 24 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: 978-1-68038-958-6

Epilepsy Drugs Market Growth & Trends:

The global epilepsy drugs market size is expected to reach USD 15.35 billion by 2030, registering a CAGR of 5.1% from 2023 to 2030, according to a new report by Grand View Research, Inc. The rising government funding for the development of new and effective drugs for the treatment of seizures is a high impact rendering driver for the epilepsy drugs market growth. The American Epilepsy Society (AES) in alliance with other organizations, such as American Academy of Neurology, the Epilepsy Foundation, and the Grass Foundation, provide funding for R&D activities and offer treatment line awareness trainingto the physicians through different programs.

Furthermore, various awareness programs conducted by organizations, such as the Epilepsy Foundation, the American Epilepsy Society, Epilepsy Association of Central Florida, CURE Epilepsy, and the Anita Kaufmann Foundation, further accelerate the diagnosis and treatment rates. This is expected to propel the market growth over the forecast period.

Epilepsy Drugs Market Report Highlights:

  • Second generation anti-epileptics are expected to be the second-fastest-growing segment. This segment includes Lamotrigine (Lamictal), Levetiracetam (Keppra), Brivaracetam (Briviact), and Perampanel (Fycompa).
  • The third generation anti-epileptics segment accounted for the largest revenue share of around 39.3% in 2022. The major factors responsible for the growth of this segment include the launch of high efficacy drugs with improved mechanism of action and fewer side effects, and the awaited launch of new pipeline drugs.
  • North America dominated the market with the largest revenue share of around 45% in 2022. The high prevalence of epilepsy in the region, with a significant number of people affected by the condition, is a major driving factor for the epilepsy drugs market.
  • Asia Pacific is estimated to expand at the highest CAGR of 6.3% over the forecast period. The presence of favorable government initiatives such as the Intersectoral Global Action Plan on Epilepsy, Global Campaign Against Epilepsy, and others, as well as the launch of new-generation anti-epileptic drugs are the drivers expected to propel the growth of this market in the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. Regional scope
    • 1.1.3. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Penetration & Growth Prospect Mapping
  • 3.5. Global Epilepsy Drug Market Analysis Tools
    • 3.5.1. Industry Analysis - Porter's Five Forces
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis
      • 3.5.2.1. Political landscape
      • 3.5.2.2. Technological landscape
      • 3.5.2.3. Economic landscape

Chapter 4. Epilepsy Drugs Market: Product Estimates & Trend Analysis

  • 4.1. Epilepsy Drug Market: Key Takeaways
  • 4.2. Epilepsy Drug Market: Product Movement & Market Share Analysis, 2022 & 2030
  • 4.3. First Generation Anti-epileptics
    • 4.3.1. First generation anti-epileptics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Second Generation Anti-epileptics
    • 4.4.1. Second generation anti-epileptics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Third Generation Anti-epileptics
    • 4.5.1. Third generation anti-epileptics market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Epilepsy Drugs Market: Regional Estimates & Trend Analysis, by Drug

  • 5.1. Regional Outlook
  • 5.2. Epilepsy Drug Market by Region: Key Marketplace Takeaways
  • 5.3. North America
    • 5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.2. U.S.
      • 5.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.3. Canada
      • 5.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.4. Europe
    • 5.4.1. UK
      • 5.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.2. Germany
      • 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.3. France
      • 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.4. Italy
      • 5.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.5. Spain
      • 5.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.6. Sweden
      • 5.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.7. Norway
      • 5.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.8. Denmark
      • 5.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.5. Asia Pacific
    • 5.5.1. Japan
      • 5.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.2. China
      • 5.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.3. India
      • 5.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.4. Australia
      • 5.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.5. Thailand
      • 5.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.6. South Korea
      • 5.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.6. Latin America
    • 5.6.1. Brazil
      • 5.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.2. Mexico
      • 5.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.3. Argentina
      • 5.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.7. MEA
    • 5.7.1. Saudi Arabia
      • 5.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.2. South Africa
      • 5.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.3. UAE
      • 5.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.4. Kuwait
      • 5.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Market Participant Categorization
    • 6.2.1. UCB S.A., Belgium
      • 6.2.1.1. Company Overview
      • 6.2.1.2. Financial Performance
      • 6.2.1.3. Product Benchmarking
      • 6.2.1.4. Strategic Initiatives
    • 6.2.2. Sanofi
      • 6.2.2.1. Company Overview
      • 6.2.2.2. Financial Performance
      • 6.2.2.3. Product Benchmarking
      • 6.2.2.4. Strategic Initiatives
    • 6.2.3. Pfizer, Inc.
      • 6.2.3.1. Company Overview
      • 6.2.3.2. Financial Performance
      • 6.2.3.3. Product Benchmarking
      • 6.2.3.4. Strategic Initiatives
    • 6.2.4. Otsuka America Pharmaceutical, Inc.
      • 6.2.4.1. Company Overview
      • 6.2.4.2. Financial Performance
      • 6.2.4.3. Product Benchmarking
      • 6.2.4.4. Strategic Initiatives
    • 6.2.5. Eisai Co., Ltd.
      • 6.2.5.1. Company Overview
      • 6.2.5.2. Financial Performance
      • 6.2.5.3. Product Benchmarking
      • 6.2.5.4. Strategic Initiatives
    • 6.2.6. Novartis AG
      • 6.2.6.1. Company Overview
      • 6.2.6.2. Financial Performance
      • 6.2.6.3. Product Benchmarking
      • 6.2.6.4. Strategic Initiatives
    • 6.2.7. Abbott Laboratories, Inc.
      • 6.2.7.1. Company Overview
      • 6.2.7.2. Financial Performance
      • 6.2.7.3. Product Benchmarking
      • 6.2.7.4. Strategic Initiatives
    • 6.2.8. Sanofi Aventis S.A.
      • 6.2.8.1. Company Overview
      • 6.2.8.2. Financial Performance
      • 6.2.8.3. Product Benchmarking
      • 6.2.8.4. Strategic Initiatives
    • 6.2.9. GlaxoSmithKline plc
      • 6.2.9.1. Company Overview
      • 6.2.9.2. Financial Performance
      • 6.2.9.3. Product Benchmarking
      • 6.2.9.4. Strategic Initiatives
    • 6.2.10. Sunovion Pharmaceuticals, Inc.
      • 6.2.10.1. Company Overview
      • 6.2.10.2. Financial Performance
      • 6.2.10.3. Product Benchmarking
      • 6.2.10.4. Strategic Initiatives
    • 6.2.11. Jazz Pharmaceuticals plc
      • 6.2.11.1. Company Overview
      • 6.2.11.2. Financial Performance
      • 6.2.11.3. Product Benchmarking
      • 6.2.11.4. Strategic Initiatives
    • 6.2.12. Neurelis, Inc.
      • 6.2.12.1. Company Overview
      • 6.2.12.2. Financial Performance
      • 6.2.12.3. Product Benchmarking
      • 6.2.12.4. Strategic Initiatives